Bifogade filer
Kurs
-15,59%
Kurs
-15,59%
Open
1,38
High
1,38
Low
1,10
Close
1,25
Kursutveckling under dagen för detta pressmeddelande
(SEK).
Likviditet
0,13 MSEK
Likviditet
0,13 MSEK
Rel. mcap
0,37%
Antal aktier
103 148
Likviditet under dagen för detta pressmeddelande
Kalender
Tid* | ||
2024-02-29 | - | Bokslutskommuniké 2023 |
2023-11-23 | - | Kvartalsrapport 2023-Q3 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-06-30 | - | Årsstämma |
2023-05-31 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2023-02-28 | - | Bokslutskommuniké 2022 |
2023-02-09 | - | Extra Bolagsstämma 2022 |
2022-11-24 | - | Kvartalsrapport 2022-Q3 |
2022-08-26 | - | Kvartalsrapport 2022-Q2 |
2022-05-20 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2022-05-19 | - | Årsstämma |
2022-05-11 | - | Kvartalsrapport 2022-Q1 |
2022-02-25 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-07-16 | - | Kvartalsrapport 2021-Q2 |
2021-06-17 | - | Årsstämma |
2021-05-27 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2021-05-07 | - | Kvartalsrapport 2021-Q1 |
2021-02-10 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-07-17 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-15 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-15 | - | Kvartalsrapport 2019-Q3 |
2019-08-19 | - | Extra Bolagsstämma 2019 |
2019-08-15 | - | Kvartalsrapport 2019-Q2 |
2019-05-31 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2019-05-29 | - | Årsstämma |
2019-05-15 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-30 | - | Kvartalsrapport 2018-Q3 |
2018-08-31 | - | Kvartalsrapport 2018-Q2 |
2018-06-14 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2018-06-13 | - | Årsstämma |
2018-05-31 | - | Kvartalsrapport 2018-Q1 |
2018-02-28 | - | Bokslutskommuniké 2017 |
2017-11-28 | - | Kvartalsrapport 2017-Q3 |
2017-11-15 | - | Extra Bolagsstämma 2017 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-06-09 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2017-06-08 | - | Årsstämma |
2017-05-31 | - | Kvartalsrapport 2017-Q1 |
2017-02-20 | - | Bokslutskommuniké 2016 |
2016-11-30 | - | Kvartalsrapport 2016-Q3 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
2016-06-01 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2016-05-31 | - | Årsstämma |
2016-05-31 | - | Kvartalsrapport 2016-Q1 |
2016-02-29 | - | Bokslutskommuniké 2015 |
2016-01-21 | - | Extra Bolagsstämma 2016 |
2015-11-30 | - | Kvartalsrapport 2015-Q3 |
2015-08-31 | - | Kvartalsrapport 2015-Q2 |
2015-06-12 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2015-06-11 | - | Årsstämma |
2015-05-28 | - | Kvartalsrapport 2015-Q1 |
2015-02-27 | - | Bokslutskommuniké 2014 |
2014-11-28 | - | Kvartalsrapport 2014-Q3 |
2014-09-12 | - | Extra Bolagsstämma 2014 |
2014-08-29 | - | Kvartalsrapport 2014-Q2 |
2014-06-10 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2014-06-09 | - | Årsstämma |
2014-05-23 | - | Kvartalsrapport 2014-Q1 |
2014-03-05 | - | Bokslutskommuniké 2013 |
2013-11-29 | - | Kvartalsrapport 2013-Q3 |
2013-09-04 | - | Kvartalsrapport 2013-Q2 |
2013-05-31 | - | Kvartalsrapport 2013-Q1 |
2013-05-08 | - | Split RLS 10:1 |
2013-04-11 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2013-04-10 | - | Årsstämma |
2013-03-05 | - | Bokslutskommuniké 2012 |
2012-11-26 | - | Kvartalsrapport 2012-Q3 |
2012-08-31 | - | Kvartalsrapport 2012-Q2 |
2012-06-12 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2012-06-11 | - | Årsstämma |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
2023-05-31 08:30:00
JANUARY 1st - MARCH 31st (Previous year in brackets)
- Net sales amounted to TSEK 89 (TSEK 305)
- Earnings before interest and taxes (EBIT) amounted to MSEK -7,5 (MSEK -5,3)
- Earnings per share after dilution at SEK -0,09 (SEK 0,07)
- Cash flow from operating activities amounted to TSEK -7 084 (TSEK -6 730)
- Liquid assets at the end of the period MSEK 13,4 (MSEK 4,7)
- Equity ratio was 82 % (77 %)
- An extra AGM was held 9 February.
- Lars Johansson was elected Board Member and Chairman of the Board at the extra AGM.
- Wounds UK publishes the peer-reviewed article "The in vitro antibiofilm performance of ChloraSolv® Wound Debridement Gel". The article concludes that ChloraSolv wound debridement gel shows notably greater antibiofilm activity, in vitro, compared to other debridement products and techniques.
- The UK MHRA (Medicines & Healthcare products Regulatory Agency) has approved RLS' application to extend the current clinical study for pressure ulcers to UK.
- Eva Jagenheim leaves her role as CFO in RLS Global AB. She will remain in service during her notice period, at latest to October, to ensure a smooth transition to her successor.
The Interim Report Q1, 2023, is enclosed and is also available at https://rls.global/financial-information/financial-reports-eng/
Publication
This information was submitted for publication through the agency of the below contact person, at 08.30 CET on May 31st 2023.
TRADING PLACE AND CERTIFIED ADVISER:
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17[th] May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.
FOR MORE INFORMATION, PLEASE CONTACT:
Björn Larsson, CEO, RLS Global
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25
Eva Jagenheim, CFO, RLS Global
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57